Focused On-demand Library for Tumor necrosis factor receptor superfamily member 10B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Death receptor 5; TNF-related apoptosis-inducing ligand receptor 2

Alternative UPACC:

O14763; O14720; O15508; O15517; O15531; Q6UXM8; Q7Z360; Q9BVE0


Tumor necrosis factor receptor superfamily member 10B, also known as Death receptor 5 and TNF-related apoptosis-inducing ligand receptor 2, plays a pivotal role in apoptosis. It acts as a receptor for the cytotoxic ligand TNFSF10/TRAIL, initiating a cascade of caspases mediating apoptosis and promoting NF-kappa-B activation. Essential for ER stress-induced apoptosis, its function underscores the balance between cell survival and death.

Therapeutic significance:

Squamous cell carcinoma of the head and neck, a non-melanoma skin cancer, may be influenced by variants affecting this protein. Understanding the role of Tumor necrosis factor receptor superfamily member 10B could open doors to potential therapeutic strategies targeting this malignancy.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.